Compare ESPR & RRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | RRBI |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 591.3M |
| IPO Year | 2013 | 2019 |
| Metric | ESPR | RRBI |
|---|---|---|
| Price | $2.64 | $90.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.60 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 5.0M | 52.9K |
| Earning Date | 03-10-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | ★ 60.71 | 28.89 |
| EPS | N/A | ★ 6.38 |
| Revenue | ★ $403,135,000.00 | N/A |
| Revenue This Year | $2.92 | $12.72 |
| Revenue Next Year | N/A | $4.35 |
| P/E Ratio | ★ N/A | $14.09 |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.73 | $46.33 |
| 52 Week High | $4.18 | $93.90 |
| Indicator | ESPR | RRBI |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 54.83 |
| Support Level | $2.37 | $86.68 |
| Resistance Level | $3.02 | $92.74 |
| Average True Range (ATR) | 0.18 | 2.43 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 54.44 | 64.11 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.